ChainGen Bio Secures New Round of Funding to Advance Next-Generation Drug Delivery Platforms

Recently, ChainGen Bio (Shanghai) Co., Ltd. (“ChainGen Bio”) successfully completed a new round of financing, with exclusive investment from Phase I of the Zhangjiang Life and Health Industry Incubation Angel Fund (“Zhangke Hemiao Fund”).

Jiajin Biologics focuses on drug conjugation and delivery technologies. It pioneered the development of antibody–oligonucleotide conjugates in China, filling the gap in extrahepatic delivery of nucleic acid therapeutics and bringing hope to patients with neuromuscular diseases who have long faced limited treatment options. Furthermore, Jiajin Biologics’ Brainferry platform, a brain-penetrating peptide technology, has the potential to help macromolecular drugs, including oligonucleotides, cross the blood–brain barrier, ushering in transformative advances in the treatment of a broader range of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.

The lead investor in this round, Zhangke Hemiao Fund, is an angel fund established within the Zhangjiang Group system by Zhangjiang Sci-Tech Investment to promote the life and health industry. It focuses on early-stage investments in advantageous sectors such as innovative drugs, cell and gene therapy, synthetic biology, and medical devices.

Dr. Wu Hao, CEO of Jiajin Biotech“Jiajin Biopharma was born in Zhangjiang and received robust incubation support from the Zhangjiang Group system since its inception. This round of financing will undoubtedly further accelerate Jiajin Biopharma’s growth in Zhangjiang, a hotbed of scientific and technological innovation. We appreciate the recognition from Zhangke Hemiao Fund; the addition of new investors is highly significant for the company during the industry downturn. With the funds raised in this round, we will recruit top-tier talent, vigorously advance intellectual property and pipeline development, and complete the clinical validation of our first product. Oligonucleotide therapeutics represent the ‘third wave of new drug discovery,’ following small-molecule drugs and antibody-based therapies, and hold immense therapeutic potential.”

Looking ahead, Chinese companies will continue to maintain their long-term advantages in R&D efficiency and cost over foreign peers. Jiajin Bio will consistently generate globally competitive patents and leading innovative drug products, bringing benefits to patients worldwide and delivering returns to shareholders.

The Zhangke Hemiao Fund, with Zhangjiang Sci-Tech Investment as its cornerstone investor, represents a significant exploration by Zhangjiang Sci-Tech Investment in promoting the deep integration of “incubation + investment.” By adopting the strategy of “investing early, investing in small enterprises, and investing in innovations,” the fund guides and anchors industrial development directions, helps Zhangjiang Sci-Tech Investment build a full-chain accelerated sci-tech innovation service system, addresses capital gaps in the stage of achievement transformation, forms a closed-loop synergy between incubation and investment, and drives “patient capital” into seed-stage and start-up technology enterprises.

Jiajin Biologics is a biotechnology company engaged in the research and development of innovative drugs. Established in January 2022, it holds full independent intellectual property rights in two core technological areas: antibody-oligonucleotide conjugates (AOCs) and brain-targeted delivery systems. Jiajin Biologics operates a 600-square-meter R&D laboratory in Zhangjiang and has established a wholly-owned subsidiary in Suzhou. The company adheres to a flat organizational structure and an operational model characterized by a high signal-to-noise ratio—prioritizing R&D substance over managerial bureaucracy. Its first pipeline candidate is expected to enter clinical trials in 2024.